Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan

[1] Coluzzi F(2020)Naldemedine: A New Option for OIBD J Pain Res 13 1209-1222

[2] Scerpa MS(2019)Pathophysiology and management of opioid-induced constipation: European expert consensus statement United European Gastroenterol J 7 7-20

[3] Pergolizzi J(2019)Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain Clin J Pain 35 174-188

[4] Farmer AD(2020)Blood-brain barrier: mechanisms governing permeability and interaction with peripherally acting μ-opioid receptor antagonists Reg Anesth Pain Med 45 688-695

[5] Drewes AM(2019)Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation Neurogastroenterol Motil. 31 e13563-564

[6] Chiarioni G(2017)Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, Phase 3, double-blind, randomised, parallel-group trials Lancet Gastroenterol Hepatol 2 555-3866

[7] De Giorgio R(2017)Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer J Clin Oncol 3 3859-994

[8] O'Brien T(2018)Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study Pain 159 987-138

[9] Morlion B(2019)Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label phase III studies J Pain Res 12 127-1467

[10] Tack J(2018)Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer Ann Oncol 29 1461-1928

[1] Coluzzi F(2020)Naldemedine: A New Option for OIBD J Pain Res 13 1209-1222

[2] Scerpa MS(2019)Pathophysiology and management of opioid-induced constipation: European expert consensus statement United European Gastroenterol J 7 7-20

[3] Pergolizzi J(2019)Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain Clin J Pain 35 174-188

[4] Farmer AD(2020)Blood-brain barrier: mechanisms governing permeability and interaction with peripherally acting μ-opioid receptor antagonists Reg Anesth Pain Med 45 688-695

[5] Drewes AM(2019)Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation Neurogastroenterol Motil. 31 e13563-564

[6] Chiarioni G(2017)Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, Phase 3, double-blind, randomised, parallel-group trials Lancet Gastroenterol Hepatol 2 555-3866

[7] De Giorgio R(2017)Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer J Clin Oncol 3 3859-994

[8] O'Brien T(2018)Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study Pain 159 987-138

[9] Morlion B(2019)Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label phase III studies J Pain Res 12 127-1467

[10] Tack J(2018)Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer Ann Oncol 29 1461-1928